Executive Summary
Procedural volume still shapes TAVR outcomes at one year, with low-volume hospitals (≤52/year) carrying 10% higher odds of death and stroke in a 215,335-patient STS/ACC TVT Registry analysis — a finding that lands as Abbott's Q2 beat sent ABT up 10.7% on heart-device strength and Edwards heads into July 23 earnings. The volume signal complicates the ESC 2025 push to make TAVI the primary strategy for tricuspid AS at age ≥70, since expansion into community centers is exactly where the volume-outcome curve bites hardest. Meanwhile, a 125-patient TRI-FR analysis shows tricuspid TEER unloads the left atrium anatomically but fails to restore LA mechanics — which tightens the case for early referral before atrial function is lost, and complicates the ESC 2025 Class IIa endorsement of transcatheter tricuspid therapy for symptomatic severe TR.
- Low-volume TAVR operators (≤11/year) had 16% higher stroke odds vs high-volume operators in the STS/ACC TVT contemporary cohort [link].
- Tricuspid TEER reduced LA volume acutely but LA reservoir strain worsened and filling pressure surrogates rose at 12 months (N=125, TRI-FR) [link].
- In a real-world 1,050-patient valve-in-valve TAVI registry, oral anticoagulation regimens carried 2.76-fold higher 12-month MACCE vs single antiplatelet therapy [link].
- Active cancer independently raised post-TAVI mortality (HR 1.64) in a 7,000-patient meta-analysis, sharpening cardio-oncology selection [link].
- Aortic dissection complicated 0.38% of 2,646 TAVR procedures with 40% 30-day mortality in a single-center series [link].
What to watch: Edwards Lifesciences Q2 earnings on July 23 will test whether transcatheter mitral and tricuspid volumes are absorbing the field's shift from TAVR-only franchises.
Aortic Valve (TAVR/TAVI)
The volume-outcome curve for TAVR has not flattened despite a decade of technique maturation. The STS/ACC TVT Registry analysis of 215,335 commercial TAVR patients (2020-2022) found low-volume hospitals (≤52/year) had adjusted odds ratios of 1.10 for 1-year mortality, stroke, and readmission versus high-volume centers (≥102/year). Low-volume operators (≤11/year) carried 16% higher stroke odds. This lands directly against the ESC 2025 expansion of TAVI as the primary strategy for tricuspid-anatomy patients ≥70 (Class I) — a recommendation that will pull volume into precisely the community hospitals where this signal is strongest. ACC/AHA 2020's more conservative >80 or shared-decision 65-80 framework looks better aligned with the volume data.
A separate Australasian valve-in-valve TAVI registry (N=1,050) found oral anticoagulation regimens carried 2.76-fold higher 12-month MACCE versus single antiplatelet therapy (observational, confounded by baseline comorbidity). And a meta-analysis of 7,000+ cancer patients confirmed active malignancy independently raises post-TAVI mortality (HR 1.64) — reinforcing that "TAVI for everyone ≥70" oversimplifies the shared-decision reality. A single-center series flagged aortic dissection in 0.38% of 2,646 TAVR cases with 40% mortality, a reminder that catastrophic complications persist. The ALERT trial in JACC tested AI-flagging of severe AS on echo to close referral gaps — a scale-up strategy that only helps if the receiving centers have the volume to deliver.
Mitral Valve (MitraClip, PASCAL, TMVR)
The transcatheter mitral space remains dominated by anatomically-difficult cases where surgical alternatives are constrained. An 11-patient BATMAN-facilitated valve-in-MAC TMVR series reported 100% technical success but 36.4% 30-day all-cause mortality — reflecting the underlying severity of native MAC disease rather than device failure. Surgical MV replacement in severe MAC carries comparable or worse mortality; both guidelines acknowledge this as a domain without a satisfactory answer, and the ESC 2025 Class IIb rating for TMVI in degenerative MS with MAC at experienced centers captures the equipoise. A separate case report of TENDYNE TMVR complicated by HIT-driven prosthetic thrombosis requiring surgical explant highlights the persistent thrombogenicity concern with early-generation transcatheter mitral prostheses — a gap that surgical bioprostheses do not carry to the same degree during the endothelialization window. NCT07709208, a new Jena-sponsored trial of TEER for exercise-induced severe MR (N=246, not yet recruiting), targets a phenotype largely absent from COAPT and RESHAPE-HF2 selection criteria.
Tricuspid Valve (TriClip, TTVR)
[NOTABLE] Tricuspid TEER unloads the atrium anatomically but does not restore its function, and this dissociation should temper the ESC 2025 Class IIa endorsement. In the TRI-FR trial and registry (N=125, median age 78), LA volume index dropped 8.1 mL/m² immediately post-T-TEER but the reduction was not sustained at 12 months. More concerning: peak atrial longitudinal strain deteriorated (−1.2%), E/e' rose 3.26 points acutely, LA stiffness remained elevated at 12 months, and forward stroke volume did not improve. The mechanistic implication is that transcatheter TR reduction may correct the regurgitant lesion without reversing the atrial myopathy that drove much of the symptom burden — consistent with the QoL-driven benefit signal in TRILUMINATE and Tri.Fr rather than hard outcome improvement.
A separate multicenter registry of 1,295 severe TR patients found only 21% were qualified for TR intervention and just 40% received Heart Team evaluation — the "too-late-referral" problem both guidelines flag. Secondary atrial TR (37%) was the most common etiology. ESC 2025 upgraded surgical TV repair for symptomatic severe primary TR to Class I; ACC/AHA 2020 still rates this IIa. The TRI-FR mechanistic findings argue for earlier referral, but the current data supports that push more strongly for surgery than for transcatheter therapy given the incomplete functional recovery. An imaging review underscores the imaging-intensive nature of TTVI selection.
Surgical vs. Transcatheter Comparisons
No head-to-head trials landed today. The day's transcatheter findings — TAVR volume-outcome sensitivity, incomplete atrial reverse remodeling after T-TEER, high early mortality with valve-in-MAC TMVR — collectively argue that the current guideline expansion of transcatheter indications (ESC 2025 age ≥70 for TAVI, Class I for T-TEER in eligible SMR) is running ahead of the granular procedural and mechanistic data. Surgical AVR at experienced centers remains the ACC/AHA-preferred option for patients <65 with tricuspid AV, and the volume data suggests that the "experienced center" qualifier applies just as forcefully to TAVR.
Preprint Highlights
The STS/ACC TVT volume analysis (medRxiv) is the day's most consequential preprint for structural heart practice. Beyond the headline volume-outcome findings, median annual hospital volume was 74 and median operator volume was 16 — meaning most TAVR in the US happens at centers below what recent RCT enrollment sites would qualify as high-volume. The finding that operator volume affected stroke but not readmission suggests procedural technique (embolic protection use, wire manipulation, valve deployment precision) drives the neurologic signal, while hospital-level factors (heart team, post-procedure care) drive the readmission and mortality signals separately.
Device & Technology
A JACC Cardiovascular Interventions post-hoc analysis of self-expanding supra-annular TAVI reports paravalvular regurgitation improves over time — relevant to durability arguments but no abstract available for critical read. A new SALZBURG risk score (585 derivation, 117 validation) predicted 3-year post-TAVI mortality with AUC 0.66, outperforming STS and EuroSCORE II — modest discrimination, but useful because existing surgical scores were not designed for this population. And 4D flow CMR data confirmed TAVR increases ascending aortic and brachiocephalic flow specifically in low-flow AS patients — physiologic support for early intervention in the low-flow phenotype where ESC 2025 already gives IIa endorsement.
Regulatory & Policy
Edwards Lifesciences paid $10M and adopted an antitrust compliance program under an FTC judgment — the settlement follows enforcement action tied to structural heart competitive practices and adds compliance overhead entering next week's earnings.
Industry & Market
Abbott raised full-year EPS guidance on Q2 strength in diagnostics and heart devices, driving a 10.7% single-day pop and validating the diversified structural heart franchise thesis. Mizuho raised Edwards' target to $105 from $100 (Outperform) ahead of the July 23 print, with consensus expecting ±5% post-earnings volatility.
Financial Analysis
The market is bifurcating structural heart names on portfolio breadth. Abbott's 10.7% gain and Medtronic's 3.8% rebound came on the same day as broad multiples compression across single-franchise names — Boston Scientific down 51% over six months, Edwards essentially flat. The clinical read-through: Wall Street is starting to price in the ESC 2025 expansion of transcatheter tricuspid and mitral indications not as a rising tide but as a competitive redistribution. Companies with combined TAVR + M-TEER + T-TEER + TTVR pipelines (Abbott, Edwards) capture the ESC upgrade of TEER for ventricular SMR to Class I and the new IIa for transcatheter TR. Single-franchise exposure is being punished. Boston Scientific's -51% move reflects this — despite strong LAA occlusion (Watchman) franchise, structural heart valve exposure is limited. Edwards enters Q2 print with 5.25% six-month appreciation and a $98.8 consensus target; the July 23 call will need to show M-TEER and T-TEER growth offsetting any TAVR share loss.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close $87.84, +0.65% on the day, +5.25% over six months
- Market cap $50.6B; trailing P/E 47.23; forward P/E 26.13; beta 0.85
- 52-week range $72.30-$96.29
- Analyst consensus target $98.80 (25 analysts, buy)
- Q2 earnings July 23: EPS est $0.74, revenue est $1.70B
- Mizuho raised target to $105 from $100 this week; FTC $10M antitrust settlement adds compliance overhead. TAVR franchise remains under structural pressure from ESC 2025 age-70 threshold expansion favoring competitors with community-hospital footprint.
Medtronic (MDT)
- Close $83.56, +3.84% on the day, -13.79% over six months
- Market cap $107.0B; trailing P/E 21.54; forward P/E 13.05; beta 0.58
- 52-week range $73.31-$106.33
- Analyst consensus target $97.84 (25 analysts, buy)
- Q1 FY27 earnings August 18: EPS est $1.39, revenue est $9.55B
- Evolut self-expanding TAVR franchise benefits from paravalvular regurgitation improvement-over-time data reported today in JACC Cardiovascular Interventions. Sponsored the AI-echo ALERT trial with Cardiovascular Business webinar July 22 — a direct play at community-hospital TAVR referral capture.
Abbott (ABT)
- Close $98.83, +10.71% on the day, -17.32% over six months
- Market cap $172.1B; trailing P/E 25.02; forward P/E 16.32; beta 0.61
- 52-week range $81.97-$137.49
- Analyst consensus target $116.54 (24 analysts, buy)
- Q2 2026 reported today: beat and raised full-year EPS guidance on diagnostics and heart-device strength
- MitraClip and TriClip franchises benefit from ESC 2025 Class I upgrade for TEER in ventricular SMR and Class IIa for transcatheter TR. The 10.7% pop reflects Street repricing of diversified structural heart exposure.
Boston Scientific (BSX)
- Close $44.62, +3.67% on the day, -51.07% over six months
- Market cap $66.3B; trailing P/E 17.99; forward P/E 12.03; beta 0.58
- 52-week range $42.20-$109.50
- Analyst consensus target $72.50 (28 analysts, strong buy)
- Q2 earnings July 29: EPS est $0.83, revenue est $5.37B
- Six-month drawdown of 51% reflects Sentinel/ACURATE structural heart franchise concerns and Watchman peri-device leak challenges highlighted in the JACC Case Reports coil-closure paper today. Analyst consensus remains strong buy — the gap between price and target is the widest in the group.
Anteris Technologies (AVR.AX)
- Close $11.56 AUD, -7.45% on the day, +57.71% over six months
- Market cap $1.1B; forward P/E -5.30; beta 0.73
- 52-week range $4.74-$15.47
- Single-analyst target $13.00
- DurAVR early clinical data driving the six-month appreciation, though today's pullback reflects profit-taking. Bicuspid valve indication remains the differentiator versus incumbent TAVR platforms.
Market outlook: The ESC 2025 guideline expansion is creating winners and losers within structural heart. Diversified franchises (Abbott's MitraClip/TriClip + Medtronic's Evolut + Edwards' SAPIEN/PASCAL) capture the M-TEER Class I and T-TEER Class IIa upgrades, while single-franchise names see multiples compression. Edwards Q2 on July 23 is the next catalyst; Boston Scientific July 29 follows.
Clinical Trial Updates
Mitral Repair
- NCT07709208 — Mitral Valve Edge-to-Edge Repair in Patients With Exercise-Induced Severe Mitral Regurgitation. Not yet recruiting, N=246, sponsored by Jena University Hospital. Interventions: GDMT vs mitral TEER. Targets a phenotype outside COAPT/MITRA-FR/RESHAPE-HF2 selection criteria — exercise-induced severe MR is a gap in the ESC 2025 Class I recommendation for TEER in ventricular SMR, which relied on resting MR grading.
Social & Conference Highlights
Cardiovascular Business and Medtronic host a free webinar July 22 at 6 PM ET on the ALERT trial (JACC, Batchelor et al.) with Vanderbilt's Brian Lindman — testing whether AI-flagging of severe AS on echo can close TAVR referral gaps.
Next up: Edwards Q2 on July 23 will show whether M-TEER and T-TEER volume growth is offsetting TAVR competitive pressure, and whether the ESC 2025 guideline expansion is translating to booked revenue or remaining a 2027-story.